Abstract:Over the past decade, global interest in the development of therapeutic monoclonal antibodies (mAbs) has risen rapidly. As therapeutic agents, antibodies have shown marked efficacy in combatting a range of cancers and immune diseases with high target specificity and low toxicity (Carla Lucia et al. in PLoS ONE 6:e24071, 2011; Donaghy in MAbs 8:659–671, 2016; Nasiri et al. in J Cell Physiol 9:6441–6457, 2018; Teo et al. in Cancer Immunol Immunother 61:2295–2309, 2012). Recent advances in cell culture technology, such as high-throughput clone screening, have facilitated antibody production at concentrations exceeding 10 g/L (Chen et al. in BMC Immunol 19:35, 2018; Huang et al. in Biotechnol Prog 26:1400–1410, 2010; Lu et al. in Biotechnol Bioeng 110:191–205, 2013; Singh et al. in Biotechnol Bioeng 113:698–716, 2016). As titers have improved, the industry has begun to focus on the adjustment of target antibody quality profiles to improve efficacy. Cell lines, culture media, and culture conditions impact protein quality (Van Beers and Bardor in Biotechnol J 7:1473–1484, 2012). Optimization of critical quality attributes (CQAs), such as charge variants, can be achieved through bioprocess development and is the preferred approach as changes to the cell line or growth media used is considered unfavorable by regulatory bodies (Gawlitzek et al. in Biotechnol Bioeng 103:1164–1175, 2009; Jordan et al. in Cytotechnology 65:31–40, 2013; Pan et al. in Cytotechnology 69:39–56, 2016). In this study, the effect of process control and ion supplementation on charge variants of mAbs produced by Chinese hamster ovary (CHO) cells was investigated. Results of this study demonstrated that the concentration of Zn<sup>2+</sup>, duration of culturing, and temperature affect charge variants of a given mAb. Under the optimum conditions of 3L bioreactors, the most significant was that Zn<sup>2 +</sup> and temperature shift could further improve the quality of antibody. The main peak increased by 12%, and the acid peak decreased by 16%. At the same time, there was no significant loss of titer. This study provided supporting evidence for methods to improve charge variants arising during mAb production.

Bioprocessing of mAb (Monoclonal Antibodies) using Chinese Hamster Ovary (CHO) Cells: A Review

Continuous Feeding Reduces the Generation of Metabolic Byproducts and Increases Antibodies Expression in Chinese Hamster Ovary-K1 Cells

Optimization of the Process of Chinese Hamster Ovary (CHO) Cell Fed-Batch Culture to Stabilize Monoclonal Antibody Production and Overall Quality: Effect of pH Control Strategies

Enhancing recombinant antibody yield in Chinese hamster ovary cells

Strategies and Considerations for Improving Recombinant Antibody Production and Quality in Chinese Hamster Ovary Cells

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Recombinant Antibody Production in CHO and NS0 Cells: Differences and Similarities

Review of the current methods of Chinese Hamster Ovary (CHO) cells cultivation for production of therapeutic protein.

Large-Scale Comparative Transcriptomic Analysis of CHO Cell Functional Adaptation to Recombinant Monoclonal Antibody Production

Production of monoclonal antibodies in COS and CHO cells

Recent advances in technology supporting biopharmaceutical production from mammalian cells

Identification of Cellular Signatures Associated with Chinese Hamster Ovary (CHO) Cell Adaptation for Secretion of Antibodies

Generation of reference cell lines, media, and a process platform for CHO cell biomanufacturing

From Efficiency to Yield: Exploring Recent Advances in CHO Cell Line Development for Monoclonal Antibodies

A comparative analysis of recombinant Fab and full‐length antibody production in Chinese hamster ovary cells

Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1

Reduction of charge variants by CHO cell culture process optimization

Increase recombinant antibody yields through optimizing vector design and production process in CHO cells

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning

Efficient mAb production in CHO cells with optimized signal peptide, codon, and UTR

Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies